These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 10098667)
1. Design, synthesis, and evaluation of azapeptides as substrates and inhibitors for human rhinovirus 3C protease. Venkatraman S; Kong J; Nimkar S; Wang QM; Aubé J; Hanzlik RP Bioorg Med Chem Lett; 1999 Feb; 9(4):577-80. PubMed ID: 10098667 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication. Kong JS; Venkatraman S; Furness K; Nimkar S; Shepherd TA; Wang QM; Aubé J; Hanzlik RP J Med Chem; 1998 Jul; 41(14):2579-87. PubMed ID: 9651162 [TBL] [Abstract][Full Text] [Related]
3. Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors. Namoto K; Sirockin F; Sellner H; Wiesmann C; Villard F; Moreau RJ; Valeur E; Paulding SC; Schleeger S; Schipp K; Loup J; Andrews L; Swale R; Robinson M; Farady CJ Bioorg Med Chem Lett; 2018 Mar; 28(5):906-909. PubMed ID: 29433930 [TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. Dragovich PS; Prins TJ; Zhou R; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Meador JW; Ferre RA; Worland ST J Med Chem; 1999 Apr; 42(7):1203-12. PubMed ID: 10197964 [TBL] [Abstract][Full Text] [Related]
5. Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation. Reich SH; Johnson T; Wallace MB; Kephart SE; Fuhrman SA; Worland ST; Matthews DA; Hendrickson TF; Chan F; Meador J; Ferre RA; Brown EL; DeLisle DM; Patick AK; Binford SL; Ford CE J Med Chem; 2000 May; 43(9):1670-83. PubMed ID: 10794684 [TBL] [Abstract][Full Text] [Related]
6. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Matthews DA; Dragovich PS; Webber SE; Fuhrman SA; Patick AK; Zalman LS; Hendrickson TF; Love RA; Prins TJ; Marakovits JT; Zhou R; Tikhe J; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; Brothers MA; DeLisle DM; Worland ST Proc Natl Acad Sci U S A; 1999 Sep; 96(20):11000-7. PubMed ID: 10500114 [TBL] [Abstract][Full Text] [Related]
7. Non-covalent inhibitors of rhinovirus 3C protease. Baxter A; Chambers M; Edfeldt F; Edman K; Freeman A; Johansson C; King S; Morley A; Petersen J; Rawlins P; Spadola L; Thong B; Van de Poël H; Williams N Bioorg Med Chem Lett; 2011 Jan; 21(2):777-80. PubMed ID: 21183345 [TBL] [Abstract][Full Text] [Related]
8. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. Dragovich PS; Prins TJ; Zhou R; Webber SE; Marakovits JT; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Ford CE; Burke BJ; Rejto PA; Hendrickson TF; Tuntland T; Brown EL; Meador JW; Ferre RA; Harr JE; Kosa MB; Worland ST J Med Chem; 1999 Apr; 42(7):1213-24. PubMed ID: 10197965 [TBL] [Abstract][Full Text] [Related]
9. A simple solid phase, peptide-based fluorescent assay for the efficient and universal screening of HRV 3C protease inhibitors. Schünemann K; Connelly S; Kowalczyk R; Sperry J; Wilson IA; Fraser JD; Brimble MA Bioorg Med Chem Lett; 2012 Aug; 22(15):5018-24. PubMed ID: 22763202 [TBL] [Abstract][Full Text] [Related]
10. Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids. Dragovich PS; Webber SE; Prins TJ; Zhou R; Marakovits JT; Tikhe JG; Fuhrman SA; Patick AK; Matthews DA; Ford CE; Brown EL; Binford SL; Meador JW; Ferre RA; Worland ST Bioorg Med Chem Lett; 1999 Aug; 9(15):2189-94. PubMed ID: 10465543 [TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics. Dragovich PS; Prins TJ; Zhou R; Johnson TO; Brown EL; Maldonado FC; Fuhrman SA; Zalman LS; Patick AK; Matthews DA; Hou X; Meador JW; Ferre RA; Worland ST Bioorg Med Chem Lett; 2002 Mar; 12(5):733-8. PubMed ID: 11858991 [TBL] [Abstract][Full Text] [Related]
12. Citrinin hydrate and radicinin: human rhinovirus 3C-protease inhibitors discovered in a target-directed microbial screen. Kadam S; Poddig J; Humphrey P; Karwowski J; Jackson M; Tennent S; Fung L; Hochlowski J; Rasmussen R; McAlpine J J Antibiot (Tokyo); 1994 Jul; 47(7):836-9. PubMed ID: 8071130 [No Abstract] [Full Text] [Related]
13. Aza-peptide Michael acceptors: a new class of inhibitors specific for caspases and other clan CD cysteine proteases. Ekici OD; Götz MG; James KE; Li ZZ; Rukamp BJ; Asgian JL; Caffrey CR; Hansell E; Dvorák J; McKerrow JH; Potempa J; Travis J; Mikolajczyk J; Salvesen GS; Powers JC J Med Chem; 2004 Apr; 47(8):1889-92. PubMed ID: 15055989 [TBL] [Abstract][Full Text] [Related]
14. Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors. Dragovich PS; Zhou R; Webber SE; Prins TJ; Kwok AK; Okano K; Fuhrman SA; Zalman LS; Maldonado FC; Brown EL; Meador JW; Patick AK; Ford CE; Brothers MA; Binford SL; Matthews DA; Ferre RA; Worland ST Bioorg Med Chem Lett; 2000 Jan; 10(1):45-8. PubMed ID: 10636240 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Reich SH; Prins TJ; Marakovits JT; Littlefield ES; Zhou R; Tikhe J; Ford CE; Wallace MB; Meador JW; Ferre RA; Brown EL; Binford SL; Harr JE; DeLisle DM; Worland ST J Med Chem; 1998 Jul; 41(15):2806-18. PubMed ID: 9667970 [TBL] [Abstract][Full Text] [Related]
16. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. Dragovich PS; Webber SE; Babine RE; Fuhrman SA; Patick AK; Matthews DA; Reich SH; Marakovits JT; Prins TJ; Zhou R; Tikhe J; Littlefield ES; Bleckman TM; Wallace MB; Little TL; Ford CE; Meador JW; Ferre RA; Brown EL; Binford SL; DeLisle DM; Worland ST J Med Chem; 1998 Jul; 41(15):2819-34. PubMed ID: 9667971 [TBL] [Abstract][Full Text] [Related]
17. Human rhinovirus 3C protease as a potential target for the development of antiviral agents. Wanga QM; Chen SH Curr Protein Pept Sci; 2007 Feb; 8(1):19-27. PubMed ID: 17305557 [TBL] [Abstract][Full Text] [Related]
18. S-nitrosothiols as novel, reversible inhibitors of human rhinovirus 3C protease. Xian M; Wang QM; Chen X; Wang K; Wang PG Bioorg Med Chem Lett; 2000 Sep; 10(18):2097-100. PubMed ID: 10999479 [TBL] [Abstract][Full Text] [Related]
19. New anti-viral drugs for the treatment of the common cold. Maugeri C; Alisi MA; Apicella C; Cellai L; Dragone P; Fioravanzo E; Florio S; Furlotti G; Mangano G; Ombrato R; Luisi R; Pompei R; Rincicotti V; Russo V; Vitiello M; Cazzolla N Bioorg Med Chem; 2008 Mar; 16(6):3091-107. PubMed ID: 18248816 [TBL] [Abstract][Full Text] [Related]
20. Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease. Kawatkar SP; Gagnon M; Hoesch V; Tiong-Yip C; Johnson K; Ek M; Nilsson E; Lister T; Olsson L; Patel J; Yu Q Bioorg Med Chem Lett; 2016 Jul; 26(14):3248-3252. PubMed ID: 27265257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]